tradingkey.logo
tradingkey.logo
Search

Beta Bionics Inc

BBNX
Add to Watchlist
21.990USD
-0.200-0.90%
Market hours 09/24, 15:21(ET)
989.33MMarket Cap
LossP/E TTM

About Beta Bionics Inc Company

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.

Beta Bionics Inc Profile

Ticker SymbolBBNX
Company nameBeta Bionics Inc
IPO dateJan 30, 2025
CEOSaint (Sean)
Number of employees291
Security typeOrdinary Share
Fiscal year-endJan 30
Address11 Hughes
CityIRVINE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92618
Phone19494277785
Websitehttps://www.betabionics.com
Ticker SymbolBBNX
IPO dateJan 30, 2025
CEOSaint (Sean)

Company Executives of Beta Bionics Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
169.63K
-2.49%
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
169.63K
-2.49%
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
169.63K
-2.49%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
94.35K
-7.27%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
94.35K
-7.27%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
94.35K
-7.27%
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Independent Director
Independent Director
29.51K
+57.49%
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Independent Director
Independent Director
29.51K
+57.49%
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Independent Director
Independent Director
29.51K
+57.49%
Mr. Sean D. Carney
Mr. Sean D. Carney
Independent Director
Independent Director
28.21K
+60.13%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
169.63K
-2.49%
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
169.63K
-2.49%
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
169.63K
-2.49%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
94.35K
-7.27%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
94.35K
-7.27%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
94.35K
-7.27%

FAQs

Who are the top five shareholders of Beta Bionics Inc?

The top five shareholders of Beta Bionics Inc are: Dr. Steven Russell, M.D., Ph.D.

How many institutions hold shares of Beta Bionics Inc (BBNX)?

As of 2026Q1, 264 institutions hold shares of Beta Bionics Inc, with a combined market value of approximately 49.25M, accounting for 110.51% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -2186348.00.

What is the biggest source of revenue for Beta Bionics Inc?

In 2026Q1, the DME channel - iLet business generated the highest revenue for Beta Bionics Inc, amounting to 12.65M and accounting for 39.52% of total revenue.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.